Sort   by:  
 Page size 
UnknownDeep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab.
Not available
S-EPMC7862054 | biostudies-literature
UnknownEvaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Not available
S-EPMC8078259 | biostudies-literature
UnknownSustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Not available
S-EPMC8796656 | biostudies-literature
UnknownPrognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Not available
S-EPMC8832474 | biostudies-literature
UnknownDaratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
Not available
S-EPMC6269302 | biostudies-literature
UnknownTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
Not available
S-EPMC10040899 | biostudies-literature
Sort   by:  
 Page size